2021-01-04,"b'$RDHL Red Hill BioPharma looks like it could be a good short squeeze candidate. 97% short float and over 11days to cover based on average daily volume. Gonna put this on the watchlist and monitor it especially for a catalyst day, could have a massive move. https://t.co/AS7jApxSY9'"
2021-01-04,"b'$RDHL $8.08 -0.48  -5.61%Opaganib COVID-19\nPhase 2/3 global trial top-line data 1Q 2021.\n$YMAB $49.51 -0.50  -1.00%Omburtamab\nCNS/Leptomeningeal Metastases from NeuroblastomaBLA Filing Early 2021 Refusal to file letter issued October 5, 2020. Expects to refile by early 2021.'"
2021-01-01,b'RT @PRNhealth: #RDHL announces positive top-line safety and efficacy data from Phase 2 #covid19 #clinicaltrial of #opaganib. More details i\xe2\x80\xa6'
2021-01-01,b'RedHill Shows Positive Results in Treating COVID-19 Pneumonia Patients\n\nRedHill $RDHL said preliminary data results from its US Phase 2 study of opaganib given to patients with #COVID19 pneumonia demonstrated positive safety &amp; efficacy.\n\n#treatment #stocks https://t.co/O0t1x0KH6p'
2021-01-01,b'Don\xe2\x80\x99t forget who called $RDHL a long  time ago and told you it\xe2\x80\x99s a nice one (especially since they are dev. a vacc pill). \n\nStarting to see mfs barely catching on. It\xe2\x80\x99s cute seeing them go through \xe2\x80\x9c eureka \xe2\x80\x9c moments \xf0\x9f\x98\x82\xf0\x9f\x98\x82\xf0\x9f\x98\x82'
2021-01-01,b'RedHill Releases \xe2\x80\x98Positive\xe2\x80\x99 Results From Early Covid-19 Trial With Opaganib; Shares Drop 5.6% https://t.co/UzEvFVDls3 $RDHL #COVID\xe3\x83\xbc19'
2021-01-01,b'StockTwits Trending Alert: Trading recent interest in REDHILL BIOPHARMA LTD. AMERICA\xc2\xa0$RDHL https://t.co/7FBNqT2xzO'
2020-12-31,"b'Evening Most Tweeted Small Caps, check out Gambiste Top 10: $BNGO $gevo $IDEX $EBON $RDHL $BTBT $ESGC $SNDL $MUX https://t.co/k3uyuEbRpJ'"
2020-12-31,b'RT @PRNhealth: #RDHL announces positive top-line safety and efficacy data from Phase 2 #covid19 #clinicaltrial of #opaganib. More details i\xe2\x80\xa6'
2020-12-31,b'RT @KingsSaddle: $RDHL RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib #Clin\xe2\x80\xa6'
2020-12-31,b'Biopharma Daily Stock Updates 12/31/20\n\n$XBI $140.78 (-2.29%) \xf0\x9f\x93\x89\n\nCOVID:\n$RDHL (-5.61%) Data from ph 2 #SARSCoV2 study\n$MRNA (-5.99%) Publication of results in NEJM\n$MRNA (-5.99%) 40M #SARSCoV2 vaccine supply agreement Korea\n\nPIPELINE:\n$AXSM (-2.15%) Initiates ph 3 trial\n\n(1/2)'
2020-12-31,b'$RDHL stock declines -5.4%. View latest news. https://t.co/pjmJ6eLp1W'
2020-12-31,b'#RDHL announces positive top-line safety and efficacy data from Phase 2 #covid19 #clinicaltrial of #opaganib. More details in the $RDHL press release: https://t.co/pHNdf63lIR #biotechnology #pharmaceuticals #healthcare'
2020-12-31,b'$RDHL RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib\nhttps://t.co/cFbMiKkeRi'
2020-12-31,b'$RDHL RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib #Clinical #Trials/Medical #Discoveries https://t.co/z2FwQkrA5U'
2020-12-31,b'$RDHL: RedHill Biopharma announced that preliminary top-line data from its U.S. Phase 2 study with... https://t.co/dcHcr8if63'
2020-12-31,"b'$RDHL \xe2\x80\x9cOpaganib targets a human cell component involved in viral replication, potentially minimizing the likelihood for resistance due to viral mutations\xe2\x80\x9d #COVID19 #coronavirus  https://t.co/uht7fHFlPX'"
2020-12-31,b'RedHill posts preliminary Phase 2 data for COVID-19 antiviral therapy $RDHL https://t.co/dxAUPi4oqy'
2020-12-31,b'RT @RedHillBio: #RDHL announces positive top-line safety and efficacy data from Phase 2 #COVID19 #clinicaltrial of #opaganib. More details\xe2\x80\xa6'
2020-12-31,b'RT @RedHillBio: #RDHL announces positive top-line safety and efficacy data from Phase 2 #COVID19 #clinicaltrial of #opaganib. More details\xe2\x80\xa6'
2020-12-31,b'RT RedHillBio: #RDHL announces positive top-line safety and efficacy data from Phase 2 #COVID19 #clinicaltrial of #opaganib. More details in the $RDHL press release: https://t.co/kjBLko8JwX'
2020-12-31,b'RedHill posts positive data from phase 2 COVID-19 study of Opaganib $RDHL https://t.co/A4z6t70BRK'
2020-12-31,b'#RDHL announces positive top-line safety and efficacy data from Phase 2 #COVID19 #clinicaltrial of #opaganib. More details in the $RDHL press release: https://t.co/QwYwR8pyep'
2020-12-31,b'$RDHL RedHill Biopharma Announces Positive Top Line Safety &amp; Efficacy Results From Phase 2 COVID 19 Study Of Opaganib https://t.co/LhYoSCJa4o'
2020-12-31,b'$RDHL Reveals Findings from Mid-Stage COVID-19 Study of Opaganib        #RedHillBiopharma    #Coronavirus    #COVID19     #SARSCoV2       https://t.co/fQTPxOTJz6'
2020-12-31,b'$RDHL  Great !!!\nRedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib\n\nhttps://t.co/b68YmKQkmM'
2020-12-31,b'Learn your lesson yet @incrediblebob12 $RDHL'
2020-12-31,b'$RDHL RedHill Biopharma (NASDAQ:RDHL) announce positive safety and efficacy data from Covid-19 study https://t.co/cNJUUPNCNR @RedHillBio #RDHL'
2020-12-31,b'$RDHL RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib https://t.co/yHzjoCFxL2'
2020-12-31,b'#RDHL announces positive top-line safety and efficacy data from Phase 2 #covid19 #clinicaltrial of #opaganib. More details in the $RDHL press release: https://t.co/MXU3KCsXxP\n#biotechnology #pharmaceuticals #healthcare'
2020-12-31,b'Moron @incrediblebob12 has no clue what news came out of $RDHL and instantly tried to pump and chase just to get fucked. Jaja losers'
2020-12-31,"b""Took a little $RDHL\n\nLet's see"""
2020-12-31,"b'RedHill Biopharma announces safety, efficacy data from Phase 2 COVID-19 study\n$RDHL'"
2020-12-31,b'Form 6-K (report of foreign issuer [rules 13a-16 and 15d-16]) filed with the SEC $RDHL https://t.co/l4YFw8ntiS'
2020-12-31,b'$RDHL RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib - News was from 3 mins ago but getting some vol here'
2020-12-31,b'$RDHL RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib https://t.co/Rr4maSFt5B'
2020-12-31,b'#RDHL announces positive top-line safety and efficacy data from Phase 2 #covid19 #clinicaltrial of #opaganib. More details in the $RDHL press release: https://t.co/YDcCSxoMpL #biotechnology #pharmaceuticals #healthcare @RedHillBio https://t.co/mp9EuYka4F'
2020-12-31,"b'$RDHL\nRedHill Bipharma Announces Positive Top-Line Safety, Efficacy Data From Phase 2 COVID-19 Study Of Opaganib\nhttps://t.co/aCfO23iJYQ'"
2020-12-31,b'New Form 6-K  entry filed by  $RDHL RedHill Biopharma Ltd  https://t.co/s5U2MIl6l4'
2020-12-31,"b""Also, if you are new to $RDHL here's a background article on Finpedia for you https://t.co/gP77EC7K3E"""
2020-12-31,b'RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib $RDHL https://t.co/LqQ3GNVmJP'
2020-12-31,b'$RDHL (Last $8.8699 (3.62%)) RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib https://t.co/rrrJLRNzP4'
2020-12-31,b'$RDHL RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib\nhttps://t.co/CZUbreH4cI\n\n#covid19'
2020-12-30,b'$RDHL was analyzed by 3 analysts. The buy consensus is at 100%. So analysts seem to be very confident about $RDHL. https://t.co/GwH5wadNcX https://t.co/ROwRajnAVJ'
2020-12-29,b'50 DMA Support today: $FBHS $FMC $RDHL ... https://t.co/aW7zteKP9U'
2020-12-29,b'$RDHL was analyzed by 3 analysts. The buy consensus is at 100%. So analysts seem to be very confident about $RDHL. https://t.co/GwH5wadNcX https://t.co/KOYQfgk6C7'
2020-12-29,b'$RDGL VIVOS INC. DISRUPTIVE CANCER TREATMENT TECHNOLOGY PENDING FDA BREAKTHROUGH DEVICE DESIGNATION https://t.co/m1PPbL5Nzy $QURE $MESO $AVRO $OGEN $APVO $CORT $ADAP $APLS $ARAV $BPTH $CDAK $ENTX $NCNA  $RDHL $VBIV $BNTX $DTIL $EIGR $ATNM $MRNA https://t.co/PFwK7FGdak'
2020-12-28,"b'https://t.co/nD4PIpLX0G\n#42sTop42\n\n2020-DEC-28 6:25pm\n$RDHL #RedHillBio Redhill up 2.25% = $7.8 million gain.\n\n(Dec 27) RedHill Biopharma Ltd. (NASDAQ:RDHL) Receives Average Recommendation of ""Hold"" from Brokerages - MarketBeat https://t.co/uXqsK3ZCRA'"
2020-12-28,"b'Today has been a good day $ALPP $ZOM $AITX $RDHL ... $AITX was my \xf0\x9f\x92\x8e in the rough. Doing the bull dance, feeling the flow #BullyBoz https://t.co/iudgcB2MSu'"
2021-01-07,b'RT @MorningBulls: Top #Israel \xf0\x9f\x87\xae\xf0\x9f\x87\xb1 - based #pharma companies listed in the US with a decreasing market cap:\n\n$TEVA ($12.15 bn)\n\n$TARO ($3.01\xe2\x80\xa6'
2021-01-07,b'Rose Above 50 DMA today: $NIB $LAND $RDHL ... https://t.co/qwiJH6vr1O'
2021-01-07,b'$RDHL RedHill Biopharma says orphan lung disease therapy RHB-204 granted Fast Track designation by US Food and Drug Administration https://t.co/99gS1HAkaC @RedHillBio #RDHL'
2021-01-07,"b""RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease $RDHL https://t.co/OMNWKUP7nT"""
2021-01-07,b'Top #Israel \xf0\x9f\x87\xae\xf0\x9f\x87\xb1 - based #pharma companies listed in the US with a decreasing market cap:\n\n$TEVA ($12.15 bn)\n\n$TARO ($3.01 bn)\n\n$GMDA ($509.6 mn)\n\n$RDHL ($306.0 mn)\n\n$SLGL ($226.3 mn)'
2021-01-06,b'Biopharma Daily Stock Updates - 01/06/20\n$XBI $143.32 (+2.04%) \xf0\x9f\x93\x88\n\nPIPELINE:\n$IMRA (-37.97%) - Ph 2a Results\n$RDHL (-3.76%) - Fast Track\n$RDUS (+15.76%) - Acquisition\n$SELB (+8.22%)  - Data\n$ZNTL (-6.54%) - Initiation\n\nFINANCE:\n$RGNX (+8.39%) - Offering\n\nhttps://t.co/kM84hB4YrB'
